8-K: Outlook Therapeutics Reports Fiscal Year 2024 Results and Provides Corporate Update

Outlook Therapeutics announced its fiscal year 2024 financial results, highlighted by the European and UK approval of LYTENAVA for wet AMD and plans for a commercial launch in 2025.

Summary

• Outlook Therapeutics reported a net loss of $75.4 million for the fiscal year ended September 30, 2024, compared to a net loss of $59.0 million in the previous year.
• The company's cash and cash equivalents stood at $14.9 million as of September 30, 2024.
• LYTENAVA, an ophthalmic formulation of bevacizumab, received marketing authorization in the European Union and the United Kingdom for the treatment of wet AMD.
• The company anticipates the first commercial launch of LYTENAVA in the first half of calendar year 2025 in the UK and Germany.
• Outlook Therapeutics expects to receive final efficacy data from the NORSE EIGHT trial in January 2025 and plans to resubmit its Biologics License Application (BLA) in the first quarter of calendar 2025.
• The company is also exploring potential licensing and partnering options for LYTENAVA outside of the US.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the regulatory approvals in the EU and UK and the planned commercial launch, but is tempered by the significant net loss and the need to resubmit the BLA. The company's future success is dependent on the upcoming data and regulatory decisions.

Positives

• LYTENAVA has received regulatory approval in the EU and UK, marking a significant milestone for the company.
• The NICE recommendation in the UK provides a positive outlook for market access.
• The company has a strategic collaboration with Cencora to support the global commercial launch of LYTENAVA.
• The company is planning to commercialize LYTENAVA directly in the EU and UK, and potentially in the US if approved.
• LYTENAVA has been granted an initial 10 years of market exclusivity in the EU and UK.

Negatives

• The company reported a significant net loss of $75.4 million for fiscal year 2024.
• The company's cash and cash equivalents have decreased to $14.9 million.
• The NORSE EIGHT trial did not meet the pre-specified non-inferiority endpoint at week 8.
• The company is still awaiting the month 3 efficacy data from the NORSE EIGHT trial.

Risks

• The company faces risks associated with developing and commercializing pharmaceutical product candidates.
• There are risks in obtaining necessary regulatory approvals, including the risk that the data from the NORSE EIGHT trial does not support the resubmission or subsequent filing by the FDA of the ONS-5010 BLA.
• The company's financial resources may not be sufficient to support its operations.
• Market conditions and macroeconomic factors, such as overseas conflicts, high interest rates, and inflation, could impact the company's business environment.

Future Outlook

The company anticipates commercial launch of LYTENAVA in the EU and UK in the first half of 2025, resubmission of the BLA in the first quarter of 2025, and potential US FDA approval in the second half of 2025. They are also exploring licensing and partnering options.

Management Comments

• Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer, stated that the team has continued to execute and progress the development of ONS-5010/LYTENAVA in Europe and the United States.
• Lawrence Kenyon also commented that the company expects to receive the month 3 NORSE EIGHT efficacy data in January 2025 and are continuing preparations for the planned resubmission of their BLA in the first quarter of calendar 2025.
• Management believes that 2025 holds significant opportunity for Outlook Therapeutics and they remain confident in the potential of ONS-5010/LYTENAVA to provide a meaningful impact globally for the treatment of wet AMD.

Industry Context

The approval of LYTENAVA addresses the need for an approved ophthalmic formulation of bevacizumab for wet AMD, as current treatments often rely on off-label repackaged versions. This positions Outlook Therapeutics to potentially capture a significant market share in the EU and UK.

Comparison to Industry Standards

• The approval of LYTENAVA in the EU and UK is a significant achievement, as it is the first and only approved ophthalmic formulation of bevacizumab for wet AMD in these regions, setting it apart from competitors who rely on off-label use.
• Companies like Roche (Avastin) and Regeneron (Eylea) have established treatments for wet AMD, but LYTENAVA's unique formulation and regulatory approval in the EU and UK provide a competitive advantage.
• The company's strategic collaboration with Cencora is similar to other pharmaceutical companies that partner with distributors to ensure efficient market access.
• The financial results, with a net loss of $75.4 million, are not uncommon for a biopharmaceutical company in the development and commercialization phase, but the decrease in cash reserves is a concern.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased cash reserves.
• Employees may be impacted by the company's financial performance and future plans.
• Customers (retina specialists and patients) will benefit from the availability of an approved treatment for wet AMD.
• Suppliers and creditors may be impacted by the company's financial situation.

Next Steps

• The company will receive final efficacy data from NORSE EIGHT in January 2025.
• The company plans to resubmit the BLA for ONS-5010 in the first quarter of calendar 2025.
• The company will initiate commercial launches in Europe in the first half of calendar 2025.
• The company will continue to assess potential licensing and partnering options.
• The company will seek potential US FDA approval of ONS-5010 in the second half of calendar 2025.

Key Dates

Keywords

LYTENAVA, ONS-5010, wet AMD, bevacizumab, ophthalmic, regulatory approval, commercial launch, NORSE EIGHT, BLA, biopharmaceutical